<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Xylocaine ®
 <br/>
Xylocaine ®
 <br/>
(lidocaine HCl Injection, USP)
 <br/>
      <br/>
Xylocaine ®
 <br/>
      <br/>
(lidocaine HCl and epinephrine Injection, USP)
</title>
   <effectiveTime value="20250422"/>
   <setId root="4dd52202-8eef-4136-92dd-ada573b7cf74"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="608775388" root="1.3.6.1.4.1.519.1"/>
            <name>Fresenius Kabi USA, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="023648251" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-482" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-485" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-486" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-492" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-495" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-482" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-485" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-486" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-492" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-495" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="840771732" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-482" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-485" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-486" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-492" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-495" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-482" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-485" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-486" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-492" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-495" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="1f949e7b-e924-4f58-bbfa-0ed1d1a297b0"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20191107"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-492" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Xylocaine

<suffix>MPF</suffix>
                        </name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LIDOCAINE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="7"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EC2CNF7XFP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIDOCAINE HYDROCHLORIDE ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="98PI200987" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LIDOCAINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-492-41" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-492-16" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20100812"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-492-43" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-492-36" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20100812"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-492-45" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-492-26" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20100812"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA006488" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100812"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38293" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PERINEURAL"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38229" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRACAUDAL"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="EPIDURAL"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INFILTRATION"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-485" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Xylocaine
</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LIDOCAINE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="7"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EC2CNF7XFP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIDOCAINE HYDROCHLORIDE ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="98PI200987" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LIDOCAINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-485-41" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-485-26" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20100812"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA006488" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100812"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INFILTRATION"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38293" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PERINEURAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-486" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Xylocaine
</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LIDOCAINE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="6"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EC2CNF7XFP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIDOCAINE HYDROCHLORIDE ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="98PI200987" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LIDOCAINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-486-41" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-486-26" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20100812"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA006488" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100812"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INFILTRATION"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38293" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PERINEURAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-482" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Xylocaine
</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.2"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="7"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4VON5FNS3C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM METABISULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EC2CNF7XFP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIDOCAINE HYDROCHLORIDE ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="98PI200987" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LIDOCAINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="0.01"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="30Q7KI53AK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EPINEPHRINE BITARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YKH834O4BH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EPINEPHRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-482-41" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-482-26" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20100812"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA006488" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100812"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INFILTRATION"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38293" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PERINEURAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-495" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Xylocaine

<suffix>MPF</suffix>
                        </name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LIDOCAINE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="6"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EC2CNF7XFP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIDOCAINE HYDROCHLORIDE ANHYDROUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="98PI200987" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LIDOCAINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-495-41" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-495-26" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20100812"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA006488" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100812"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INFILTRATION"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38293" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PERINEURAL"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38229" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRACAUDAL"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="EPIDURAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="a19f0f5c-6338-41ac-8f81-f126bb46921d">
               <id root="96c5a900-960a-d713-e053-2995a90ae267"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph/>
                  <paragraph>For Infiltration and Nerve Block</paragraph>
                  <paragraph>Rx only</paragraph>
               </text>
               <effectiveTime value="20190331"/>
            </section>
         </component>
         <component>
            <section ID="d9ae2c01-b34b-459d-8a55-6b378700cfaa">
               <id root="1e3f64fc-2178-4826-b4f1-5874efa9eb6b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION:</title>
               <text>
                  <paragraph>Xylocaine (lidocaine HCl) Injections are sterile, nonpyrogenic, aqueous solutions that contain a local anesthetic agent with or without epinephrine and are administered parenterally by injection.  See 
       
 
  
       
 
  <content styleCode="bold">
                        <linkHtml href="#d0456c31-b486-43af-9658-c6e255889f05">INDICATIONS AND USAGE</linkHtml>
                     </content> section for specific uses.

      

 
      

 </paragraph>
                  <paragraph>Xylocaine solutions contain lidocaine HCl, which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride and has the molecular wt. 270.8.  Lidocaine HCl (C
       
 
  
       
 
  <sub>14</sub>H
       
 
  
       
 
  <sub>22</sub>N
       
 
  
       
 
  <sub>2</sub>O • HCl) has the following structural formula:
      

 
      

 </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <br/>
                  <paragraph>Epinephrine is (-) -3, 4-Dihydroxy-α-[(methylamino) methyl] benzyl alcohol and has the molecular wt. 183.21.  Epinephrine (C
       
 
  
       
 
  <sub>9</sub>H
       
 
  
       
 
  <sub>13</sub>NO
       
 
  
       
 
  <sub>3</sub>) has the following structural formula: 
      

 
      

 </paragraph>
                  <paragraph> 
       
 
  
       
 
  <br/>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage forms listed as Xylocaine-MPF indicate single dose solutions that are 
        
  
   
        
  
   <content styleCode="underline">M</content>ethyl 
        
  
   
        
  
   <content styleCode="underline">P</content>araben 
        
  
   
        
  
   <content styleCode="underline">F</content>ree (MPF).
       
 
  
       
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Xylocaine MPF</content> is a sterile, nonpyrogenic, isotonic solution containing sodium chloride.  
       
 
  
       
 
  <content styleCode="underline">Xylocaine</content> in multiple dose vials:  Each mL also contains 1 mg methyl­paraben as antiseptic preservative.  The pH of these solutions is adjusted to approximately 6.5 (5.0 to 7.0) with sodium hydroxide and/or hydrochloric acid.
      

 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Xylocaine MPF with Epinephrine</content> is a sterile, nonpyrogenic, isotonic solution containing sodium chloride.  Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.  
       
 
  
       
 
  <content styleCode="underline">Xylocaine with Epinephrine</content> in multiple dose vials:  Each mL also contains 1 mg methylparaben as antiseptic preservative.  The pH of these solutions is adjusted to approximately 4.5 (3.3 to 5.5) with sodium hydroxide and/or hydrochloric acid.  Filled under nitrogen.
      

 
      

 </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>structure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>structure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="f334ba63-b169-4010-8ddf-11dfcb73f686">
               <id root="96c5a900-960c-d713-e053-2995a90ae267"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY:</title>
               <effectiveTime value="20151113"/>
               <component>
                  <section ID="df0f3278-c986-4d14-ba65-43238c5741c9">
                     <id root="96c5a900-960d-d713-e053-2995a90ae267"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>Mechanism of Action</title>
                     <text>
                        <paragraph>Lidocaine HCl stabilizes the neuronal membrane by                                    inhibiting the ionic fluxes required for the initiation and                                    conduction of impulses thereby effecting local anesthetic                                    action.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="dcad5b7c-4cce-41ac-8a3d-f8d150b54157">
                     <id root="96c5a900-960e-d713-e053-2995a90ae267"/>
                     <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
                     <title>Hemodynamics</title>
                     <text>
                        <paragraph>Excessive blood levels may cause changes in cardiac                                    output, total peripheral resistance, and mean arterial                                    pressure.  With central neural blockade these changes                                    may be attributable to block of autonomic fibers, a direct                                    depressant effect of the local anesthetic agent on various                                    components of the cardiovascular system, and/or the                                    beta-adrenergic receptor stimulating action of epinephrine when                                    present.  The net effect is normally a modest                                    hypotension when the recommended dosages are not                                    exceeded.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="ea48afaa-db55-4d28-a3b1-d63314a363fb">
                     <id root="96c5a900-960f-d713-e053-2995a90ae267"/>
                     <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
                     <title>Pharmacokinetics and Metabolism</title>
                     <text>
                        <paragraph>Information derived from diverse formulations,                                    concentrations and usages reveals that lidocaine HCl is                                    completely absorbed following parenteral administration, its                                    rate of absorption depending, for example, upon various factors                                    such as the site of administration and the presence or absence                                    of a vasoconstrictor agent.  Except for intravascular                                    administration, the highest blood levels are obtained following                                    intercostal nerve block and the lowest after subcutaneous                                    administration. </paragraph>
                        <paragraph>The plasma binding of lidocaine HCl is dependent on drug                                    concentration, and the fraction bound decreases with increasing                                    concentration.  At concentrations of 1 to 4 mcg of free                                    base per mL 60 to 80 percent of lidocaine HCl is protein                                    bound.  Binding is also dependent on the plasma                                    concentration of the alpha-1-acid glycoprotein. </paragraph>
                        <paragraph>Lidocaine HCl crosses the blood-brain and placental                                    barriers, presumably by passive diffusion. </paragraph>
                        <paragraph>Lidocaine HCl is metabolized rapidly by the liver, and                                    metabolites and unchanged drug are excreted by the                                    kidneys.  Biotransformation includes oxidative                                    N-dealkylation, ring hydroxylation, cleavage of the amide                                    linkage, and conjugation.  N-dealkylation, a major                                    pathway of biotransformation, yields the metabolites                                    monoethylglycinexylidide and glycinexylidide.  The                                    pharmacological/toxicological actions of these metabolites are                                    similar to, but less potent than, those of lidocaine                                    HCl.  Approximately 90% of lidocaine HCl                                    administered is excreted in the form of various metabolites, and                                    less than 10% is excreted unchanged.  The                                    primary metabolite in urine is a conjugate of                                    4-hydroxy-2,6-dimethylaniline. </paragraph>
                        <paragraph>The elimination half-life of lidocaine HCl following an                                    intravenous bolus injection is typically 1.5 to 2                                    hours.  Because of the rapid rate at which lidocaine                                    HCl is metabolized, any condition that affects liver function                                    may alter lidocaine HCl kinetics.  The half-life may be                                    prolonged two-fold or more in patients with liver                                    dysfunction.  Renal dysfunction does not affect                                    lidocaine HCl kinetics but may increase the accumulation of                                    metabolites.</paragraph>
                        <paragraph>Factors such as acidosis and the use of CNS stimulants                                    and depressants affect the CNS levels of lidocaine HCl required                                    to produce overt systemic effects.  Objective adverse                                    manifestations become increasingly apparent with increasing                                    venous plasma levels above 6 mcg free base per mL.  In                                    the rhesus monkey arterial blood levels of 18 to 21 mcg/mL have                                    been shown to be threshold for convulsive activity.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="d0456c31-b486-43af-9658-c6e255889f05">
               <id root="96c5a900-9610-d713-e053-2995a90ae267"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE:</title>
               <text>
                  <paragraph>Xylocaine (lidocaine HCl) Injections are indicated for production                            of local or regional anesthesia by infiltration techniques such as                            percutaneous injection and intravenous regional anesthesia by peripheral                            nerve block techniques such as brachial plexus and intercostal and by                            central neural techniques such as lumbar and caudal epidural blocks,                            when the accepted procedures for these techniques as described in                            standard textbooks are observed.</paragraph>
               </text>
               <effectiveTime value="20151113"/>
            </section>
         </component>
         <component>
            <section ID="ed349a71-ff2e-41f5-9661-61398a0c7e2c">
               <id root="96c5a900-9611-d713-e053-2995a90ae267"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS:</title>
               <text>
                  <paragraph>Lidocaine HCl is contraindicated in patients with a known history                            of hypersensitivity to local anesthetics of the amide type.</paragraph>
               </text>
               <effectiveTime value="20151113"/>
            </section>
         </component>
         <component>
            <section ID="aa184fbe-007a-49af-92f0-7028d0fa839c">
               <id root="96c5a900-9612-d713-e053-2995a90ae267"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS:</title>
               <text>
                  <paragraph>XYLOCAINE INJECTIONS FOR INFILTRATION AND NERVE BLOCK SHOULD BE EMPLOYED ONLY BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE 
       
 
  
       
 
  <content styleCode="italics">
                        <content styleCode="italics">IMMEDIATE</content>
                     </content> AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also 
       
 
  
       
 
  <content styleCode="bold">
                        <linkHtml href="#f38cf058-92bf-4b28-a704-59334a3c8cc1">ADVERSE REACTIONS</linkHtml>
                     </content> and 
       
 
  
       
 
  <content styleCode="bold">
                        <linkHtml href="#dee2ae0a-5f79-432b-b723-5b3c3e3ed2ec">PRECAUTIONS</linkHtml>
                     </content>).  DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH.
      

 
      

 </paragraph>
               </text>
               <effectiveTime value="20190331"/>
               <component>
                  <section ID="s2">
                     <id root="96c5a900-9613-d713-e053-2995a90ae267"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Methemoglobinemia
</title>
                     <text>
                        <paragraph>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.
</paragraph>
                        <paragraph>Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Xylocaine and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.
</paragraph>
                        <paragraph>Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions.  The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours.  There is insufficient information to determine whether shorter infusion periods are not associated with these findings.  The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2nd month after surgery.  Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement. </paragraph>
                        <paragraph>To avoid intravascular injection, aspiration should be performed before the local anesthetic solution is injected.  The needle must be repositioned until no return of blood can be elicited by aspiration.  Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</paragraph>
                        <paragraph>Local anesthetic solutions containing antimicrobial preservatives (e.g., methylparaben) should not be used for epidural or spinal anesthesia because the safety of these agents has not been established with regard to intrathecal injection, either intentional or accidental.</paragraph>
                        <paragraph>Xylocaine with epinephrine solutions contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.
         
 
  
         
 
  <br/>
                           <br/>Anaphylactic reactions may occur following administration of lidocaine hydrochloride (see 
         
 
  
         
 
  <content styleCode="bold">
                              <linkHtml href="#f38cf058-92bf-4b28-a704-59334a3c8cc1">ADVERSE REACTIONS</linkHtml>
                           </content>).
         
 
  
         
 
  <br/>
                           <br/>In the case of severe reaction, discontinue the use of the drug.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20190331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="dee2ae0a-5f79-432b-b723-5b3c3e3ed2ec">
               <id root="96c5a900-9614-d713-e053-2995a90ae267"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS:</title>
               <effectiveTime value="20151113"/>
               <component>
                  <section ID="f051fba9-a1f9-4e5c-8141-4fb4cc055d2e">
                     <id root="96c5a900-9615-d713-e053-2995a90ae267"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>The safety and effectiveness of lidocaine HCl depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies.  Standard textbooks should be consulted for specific techniques and precautions for various regional anesthetic procedures. </paragraph>
                        <paragraph>Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use (see 
         
 
  
         
 
  <content styleCode="bold">
                              <linkHtml href="#aa184fbe-007a-49af-92f0-7028d0fa839c">WARNINGS</linkHtml>
                           </content> and 
         
 
  
         
 
  <content styleCode="bold">
                              <linkHtml href="#f38cf058-92bf-4b28-a704-59334a3c8cc1">ADVERSE REACTIONS</linkHtml>
                           </content>).  The lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects.  Syringe aspirations should also be performed before and during each supplemental injection when using indwelling catheter techniques.  During the administration of epidural anesthesia, it is recommended that a test dose be administered initially and that the patient be monitored for central nervous system toxicity and cardiovascular toxicity, as well as for signs of unintended intrathecal administration, before proceeding.  When clinical conditions permit, consideration should be given to employing local anesthetic solutions that contain epinephrine for the test dose because circulatory changes compatible with epinephrine may also serve as a warning sign of unintended intravascular injection.  An intravascular injection is still possible even if aspirations for blood are negative.  Repeated doses of lidocaine HCl may cause significant increases in blood levels with each repeated dose because of slow accumulation of the drug or its metabolites.  Tolerance to elevated blood levels varies with the status of the patient.  Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age and physical condition.  Lidocaine HCl should also be used with caution in patients with severe shock or heart block.
        

 
        

 </paragraph>
                        <paragraph>Lumbar and caudal epidural anesthesia should be used with extreme caution in persons with the following conditions: existing neurological disease, spinal deformities, septicemia, and severe hypertension.</paragraph>
                        <paragraph>Local anesthetic solutions containing a vasoconstrictor should be used cautiously and in carefully circumscribed quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply.  Patients with peripheral vascular disease and those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response.  Ischemic injury or necrosis may result.  Preparations containing a vasoconstrictor should be used with caution in patients during or following the administration of potent general anesthetic agents, since cardiac arrhythmias may occur under such conditions.</paragraph>
                        <paragraph>Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness should be accomplished after each local anesthetic injection.  It should be kept in mind at such times that restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression or drowsiness may be early warning signs of central nervous system toxicity.   </paragraph>
                        <paragraph>Since amide-type local anesthetics are metabolized by the liver, Xylocaine Injection should be used with caution in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at greater risk of developing toxic plasma concentrations.  Xylocaine Injection should also be used with caution in patients with impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by these drugs.     </paragraph>
                        <paragraph>Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial malignant hyperthermia.  Since it is not known whether amide-type local anesthetics may trigger this reaction and since the need for supplemental general anesthesia cannot be predicted in advance, it is suggested that a standard protocol for the management of malignant hyperthermia should be available.  Early unexplained signs of tachycardia, tachypnea, labile blood pressure and metabolic acidosis may precede temperature elevation.  Successful outcome is dependent on early diagnosis, prompt discontinuance of the suspect triggering agent(s) and institution of treatment, including oxygen therapy, indicated supportive measures and dantrolene (consult dantrolene sodium intravenous package insert before using). </paragraph>
                        <paragraph>Proper tourniquet technique, as described in publications and standard textbooks, is essential in the performance of intravenous regional anesthesia.  Solutions containing epinephrine or other vasoconstrictors should not be used for this technique.</paragraph>
                        <paragraph>Lidocaine HCl should be used with caution in persons with known drug sensitivities.  Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc) have not shown cross-sensitivity to lidocaine HCl.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="b74935e9-2aeb-4025-8ad8-8bb402579a1d">
                     <id root="96c5a900-9616-d713-e053-2995a90ae267"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Use in the Head and Neck Area</title>
                     <text>
                        <paragraph>Small doses of local anesthetics injected into the head and neck area, including retrobulbar, dental and stellate ganglion blocks, may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses.  Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression have been reported.  These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation.  Patients receiving these blocks should have their circulation and respiration monitored and be constantly observed.  Resuscitative equipment and personnel for treating adverse reactions should be immediately available.  Dosage recommendations should not be exceeded (see 
         
 
  
         
 
  <content styleCode="bold">
                              <linkHtml href="#c73d1650-a10b-4fb4-82ef-e510975e8225">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="ac1b8d4a-d1f8-47b5-8927-1c2a649b17f3">
                     <id root="96c5a900-9617-d713-e053-2995a90ae267"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>When appropriate, patients should be informed in advance                                    that they may experience temporary loss of sensation and motor                                    activity, usually in the lower half of the body, following                                    proper administration of epidural anesthesia.</paragraph>
                        <paragraph>Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.
</paragraph>
                     </text>
                     <effectiveTime value="20190331"/>
                  </section>
               </component>
               <component>
                  <section ID="f7efd8b4-5bbc-420a-aa49-bfff16a4e828">
                     <id root="96c5a900-9618-d713-e053-2995a90ae267"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Clinically Significant Drug Interactions</title>
                     <text>
                        <paragraph>The administration of local anesthetic solutions                                    containing epinephrine or norepinephrine to patients receiving                                    monoamine oxidase inhibitors or tricyclic antidepressants may                                    produce severe, prolonged hypertension.</paragraph>
                        <paragraph>Phenothiazines and butyrophenones may reduce or reverse                                    the pressor effect of epinephrine.</paragraph>
                        <paragraph>Concurrent use of these agents should generally be                                    avoided.  In situations when concurrent therapy is                                    necessary, careful patient monitoring is essential.</paragraph>
                        <paragraph>Concurrent administration of vasopressor drugs (for the                                    treatment of hypotension related to obstetric blocks) and                                    ergot-type oxytocic drugs may cause severe, persistent                                    hypertension or cerebrovascular accidents.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="a1139151-04e2-45f7-837c-74aaa3c1a777">
                     <id root="96c5a900-9619-d713-e053-2995a90ae267"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>The intramuscular injection of lidocaine HCl may result                                    in an increase in creatine phosphokinase levels.  Thus,                                    the use of this enzyme determination, without isoenzyme                                    separation, as a diagnostic test for the presence of acute                                    myocardial infarction may be compromised by the intramuscular                                    injection of lidocaine HCl.</paragraph>
                        <paragraph>Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics:
</paragraph>
                        <paragraph>Examples of Drugs Associated with Methemoglobinemia:
</paragraph>
                        <table width="100%">
                           <col width="25.450%" align="left"/>
                           <col width="74.550%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Toprule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Class</content>
                                 </td>
                                 <td rowspan="2" align="left" styleCode="Toprule Botrule Rrule" valign="top">
                                    <content styleCode="bold">Examples</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Rrule" valign="top">Nitrates/Nitrites
</td>
                                 <td rowspan="2" align="left" styleCode="Botrule Rrule" valign="top">nitric oxide, nitroglycerin, nitroprusside, nitrous oxide
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Local anesthetics
</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Antineoplastic agents
</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Antibiotics
</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">dapsone, nitrofurantoin, paraaminosalicylic acid, sulfonamides
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Antimalarials
</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">chloroquine, primaquine
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Anticonvulsants
</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Phenobarbital, phenytoin, sodium valproate
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Other drugs
</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">acetaminophen, metoclopramide, quinine, sulfasalazine
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20190331"/>
                  </section>
               </component>
               <component>
                  <section ID="b7471ea0-3396-4ad9-8d6b-e7acb24104a1">
                     <id root="96c5a900-961a-d713-e053-2995a90ae267"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Studies of lidocaine HCl in animals to evaluate the                                    carcinogenic and mutagenic potential or the effect on fertility                                    have not been conducted.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="cab482ad-735d-47f0-83e1-573041998b5c">
                     <id root="96c5a900-961b-d713-e053-2995a90ae267"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>Teratogenic Effects: Pregnancy Category                                    B. </paragraph>
                        <paragraph> Reproduction studies have been performed in rats at                                    doses up to 6.6 times the human dose and have revealed no                                    evidence of harm to the fetus caused by lidocaine HCl.                                     There are, however, no adequate and well-controlled studies in                                    pregnant women.  Animal reproduction studies are not                                    always predictive of human response.  General                                    consideration should be given to this fact before administering                                    lidocaine HCl to women of childbearing potential, especially                                    during early pregnancy when maximum organogenesis takes                                    place.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="bd9a1f42-41e5-4449-98be-aa37fea1c705">
                     <id root="96c5a900-961c-d713-e053-2995a90ae267"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>Labor and Delivery</title>
                     <text>
                        <paragraph>Local anesthetics rapidly cross the placenta and when                                    used for epidural, paracervical, pudendal or caudal block                                    anesthesia, can cause varying degrees of maternal, fetal and                                    neonatal toxicity (see 
         
 
  
         
 
  <linkHtml href="#f334ba63-b169-4010-8ddf-11dfcb73f686">CLINICAL                                        PHARMACOLOGY</linkHtml>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="italics">
                                    <linkHtml href="#f334ba63-b169-4010-8ddf-11dfcb73f686">, Pharmacokinetics and Metabolism</linkHtml>
                                 </content>
                              </content>
                           </content>).  The potential for toxicity depends upon                                    the procedure performed, the type and amount of drug used, and                                    the technique of drug administration.  Adverse                                    reactions in the parturient, fetus and neonate involve                                    alterations of the central nervous system, peripheral vascular                                    tone and cardiac function. 
        

 
        

 </paragraph>
                        <paragraph>Maternal hypotension has resulted from regional                                    anesthesia.  Local anesthetics produce vasodilation by                                    blocking sympathetic nerves.  Elevating the                                    patient’s legs and positioning her on her left side                                    will help prevent decreases in blood pressure. </paragraph>
                        <paragraph>The fetal heart rate also should be monitored                                    continuously, and electronic fetal monitoring is highly                                    advisable.</paragraph>
                        <paragraph>Epidural, spinal, paracervical, or pudendal anesthesia                                    may alter the forces of parturition through changes in uterine                                    contractility or maternal expulsive efforts.  In one                                    study, paracervical block anesthesia was associated with a                                    decrease in the mean duration of first stage labor and                                    facilitation of cervical dilation.  However, spinal and                                    epidural anesthesia have also been reported to prolong the                                    second stage of labor by removing the parturient’s                                    reflex urge to bear down or by interfering with motor                                    function.  The use of obstetrical anesthesia may                                    increase the need for forceps assistance.</paragraph>
                        <paragraph>The use of some local anesthetic drug products during                                    labor and delivery may be followed by diminished muscle strength                                    and tone for the first day or two of life.  The                                    long-term significance of these observations is                                    unknown.  Fetal bradycardia may occur in 20 to 30                                    percent of patients receiving paracervical nerve block                                    anesthesia with the amide-type local anesthetics and may be                                    associated with fetal acidosis.  Fetal heart rate                                    should always be monitored during paracervical                                    anesthesia.  The physician should weigh the possible                                    advantages against risks when considering a paracervical block                                    in prematurity, toxemia of pregnancy, and fetal                                    distress.  Careful adherence to recommended dosage is                                    of the utmost importance in obstetrical paracervical                                    block.  Failure to achieve adequate analgesia with                                    recommended doses should arouse suspicion of intravascular or                                    fetal intracranial injection.  Cases compatible with                                    unintended fetal intracranial injection of local anesthetic                                    solution have been reported following intended paracervical or                                    pudendal block or both.  Babies so affected present                                    with unexplained neonatal depression at birth, which correlates                                    with high local anesthetic serum levels, and often manifest                                    seizures within six hours.  Prompt use of supportive                                    measures combined with forced urinary excretion of the local                                    anesthetic has been used successfully to manage this                                    complication.</paragraph>
                        <paragraph>Case reports of maternal convulsions and cardiovascular                                    collapse following use of some local anesthetics for                                    paracervical block in early pregnancy (as anesthesia for                                    elective abortion) suggest that systemic absorption under these                                    circumstances may be rapid.  The recommended maximum                                    dose of each drug should not be exceeded.  Injection                                    should be made slowly and with frequent aspiration.                                     Allow a 5-minute interval between sides.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="ba650bad-dbd9-43bc-8daa-2650ad4da724">
                     <id root="96c5a900-961d-d713-e053-2995a90ae267"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether this drug is excreted in human                                    milk.  Because many drugs are excreted in human milk,                                    caution should be exercised when lidocaine HCl is administered                                    to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="faab41d7-b5a5-458c-9dc8-cc25715984d5">
                     <id root="96c5a900-961e-d713-e053-2995a90ae267"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Dosages in children should be reduced, commensurate with age, body weight and physical condition, see 
         
 
  
         
 
  <content styleCode="bold">
                              <linkHtml href="#c73d1650-a10b-4fb4-82ef-e510975e8225">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="f38cf058-92bf-4b28-a704-59334a3c8cc1">
               <id root="96c5a900-961f-d713-e053-2995a90ae267"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS:</title>
               <effectiveTime value="20151113"/>
               <component>
                  <section ID="f957298a-b9d6-4d00-b1b5-1af74e601a30">
                     <id root="96c5a900-9620-d713-e053-2995a90ae267"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>Systemic</title>
                     <text>
                        <paragraph>Adverse experiences following the administration of                                    lidocaine HCl are similar in nature to those observed with other                                    amide local anesthetic agents.  These adverse                                    experiences are, in general, dose-related and may result from                                    high plasma levels caused by excessive dosage, rapid absorption                                    or inadvertent intravascular injection, or may result from a                                    hypersensitivity, idiosyncrasy or diminished tolerance on the                                    part of the patient.  Serious adverse experiences are                                    generally systemic in nature.  The following types are                                    those most commonly reported:</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="b0f7d91f-4f02-48ca-a220-7e839f27ba0a">
                     <id root="96c5a900-9621-d713-e053-2995a90ae267"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>Central Nervous System</title>
                     <text>
                        <paragraph>CNS manifestations are excitatory and/or depressant and                                    may be characterized by lightheadedness, nervousness,                                    apprehension, euphoria, confusion, dizziness, drowsiness,                                    tinnitus, blurred or double vision, vomiting, sensations of                                    heat, cold or numbness, twitching, tremors, convulsions,                                    unconsciousness, respiratory depression and arrest.                                     The excitatory manifestations may be very brief or may not occur                                    at all, in which case the first manifestation of toxicity may be                                    drowsiness merging into unconsciousness and respiratory                                    arrest.</paragraph>
                        <paragraph>Drowsiness following the administration of lidocaine HCl                                    is usually an early sign of a high blood level of the drug and                                    may occur as a consequence of rapid absorption.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="df6492d0-62bd-449e-89dd-2bba8c29710b">
                     <id root="96c5a900-9622-d713-e053-2995a90ae267"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>Cardiovascular System</title>
                     <text>
                        <paragraph>Cardiovascular manifestations are usually depressant and                                    are characterized by bradycardia, hypotension, and                                    cardiovascular collapse, which may lead to cardiac                                    arrest.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="fe9a1f07-636d-464b-a148-9e08db0b8876">
                     <id root="96c5a900-9623-d713-e053-2995a90ae267"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>Allergic</title>
                     <text>
                        <paragraph>Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions.  Allergic reactions may occur as a result of sensitivity either to local anesthetic agents or to the methylparaben used as a preservative in the multiple dose vials.  Allergic reactions, including anaphylactic reactions, may occur as a result of sensitivity to lidocaine, but are infrequent.  If allergic reactions do occur, they should be managed by conventional means.  The detection of sensitivity by skin testing is of doubtful value.
         
 
  
         
 
  <br/>
                           <br/>There have been no reports of cross sensitivity between lidocaine hydrochloride and procainamide or between lidocaine hydrochloride and quinidine.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="c99da593-0564-4984-9dc1-1de55e7a2a8b">
                     <id root="96c5a900-9624-d713-e053-2995a90ae267"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>Neurologic</title>
                     <text>
                        <paragraph>The incidences of adverse reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration and the physical status of the patient.  In a prospective review of 10,440 patients who received lidocaine HCl for spinal anesthesia, the incidences of adverse reactions were reported to be about 3 percent each for positional headaches, hypotension and backache; 2 percent for shivering; and less than 1 percent each for peripheral nerve symptoms, nausea, respiratory inadequacy and double vision.  Many of these observations may be related to local anesthetic techniques, with or without a contribution from the local anesthetic. </paragraph>
                        <paragraph>In the practice of caudal or lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter may occur.  Subsequent adverse effects may depend partially on the amount of drug administered subdurally.  These may include spinal block of varying magnitude (including total spinal block), hypotension secondary to spinal block, loss of bladder and bowel control, and loss of perineal sensation and sexual function.  Persistent motor, sensory and/or autonomic (sphincter control) deficit of some lower spinal segments with slow recovery (several months) or incomplete recovery have been reported in rare instances when caudal or lumbar epidural block has been attempted.  Backache and headache have also been noted following use of these anesthetic procedures. </paragraph>
                        <paragraph>There have been reported cases of permanent injury to extraocular muscles requiring surgical repair following retrobulbar administration.
         
 
  
         
 
  <br/>
                           <br/>
                           <content styleCode="bold">
                              <content styleCode="italics">Hematologic
           
   
    
           
   
    <br/>
                              </content>
                           </content>Methemoglobinemia.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="c4fdf818-7c1e-4d1b-a0ae-07bde0bf3ae5">
               <id root="96c5a900-9625-d713-e053-2995a90ae267"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE:</title>
               <text>
                  <paragraph>Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution (see 
       
 
  
       
 
  <content styleCode="bold">
                        <linkHtml href="#f38cf058-92bf-4b28-a704-59334a3c8cc1">ADVERSE REACTIONS,</linkHtml> 
        
  
   
        
  
   <linkHtml href="#aa184fbe-007a-49af-92f0-7028d0fa839c">WARNINGS,</linkHtml>
                     </content> and 
       
 
  
       
 
  <content styleCode="bold">
                        <linkHtml href="#dee2ae0a-5f79-432b-b723-5b3c3e3ed2ec">PRECAUTIONS</linkHtml>
                     </content>).
      

 
      

 </paragraph>
               </text>
               <effectiveTime value="20151113"/>
               <component>
                  <section ID="a6358d72-6a92-4a0f-9f07-4b1c857f6688">
                     <id root="96c5a900-9626-d713-e053-2995a90ae267"/>
                     <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
                     <title>Management of Local Anesthetic Emergencies</title>
                     <text>
                        <paragraph>The first consideration is prevention, best accomplished                                    by careful and constant monitoring of cardiovascular and                                    respiratory vital signs and the patient’s state of                                    consciousness after each local anesthetic injection.                                     At the first sign of change, oxygen should be                                    administered.</paragraph>
                        <paragraph>The first step in the management of convulsions, as well                                    as underventilation or apnea due to unintended subarachnoid                                    injection of drug solution, consists of immediate attention to                                    the maintenance of a patent airway and assisted or controlled                                    ventilation with oxygen and a delivery system capable of                                    permitting immediate positive airway pressure by mask.                                     Immediately after the institution of these ventilatory measures,                                    the adequacy of the circulation should be evaluated, keeping in                                    mind that drugs used to treat convulsions sometimes depress the                                    circulation when administered intravenously.  Should                                    convulsions persist despite adequate respiratory support, and if                                    the status of the circulation permits, small increments of an                                    ultra-short acting barbiturate (such as thiopental or thiamylal)                                    or a benzodiazepine (such as diazepam) may be administered                                    intravenously.  The clinician should be familiar, prior                                    to the use of local anesthetics, with these anticonvulsant                                    drugs.  Supportive treatment of circulatory depression                                    may require administration of intravenous fluids and, when                                    appropriate, a vasopressor as directed by the clinical situation                                    (e.g., ephedrine).</paragraph>
                        <paragraph>If not treated immediately, both convulsions and                                    cardiovascular depression can result in hypoxia, acidosis,                                    bradycardia, arrhythmias and cardiac arrest.                                     Underventilation or apnea due to unintentional subarachnoid                                    injection of local anesthetic solution may produce these same                                    signs and also lead to cardiac arrest if ventilatory support is                                    not instituted.  If cardiac arrest should occur,                                    standard cardiopulmonary resuscitative measures should be                                    instituted.</paragraph>
                        <paragraph>Endotracheal intubation, employing drugs and techniques                                    familiar to the clinician, may be indicated, after initial                                    administration of oxygen by mask, if difficulty is encountered                                    in the maintenance of a patent airway or if prolonged                                    ventilatory support (assisted or controlled) is                                    indicated.</paragraph>
                        <paragraph>Dialysis is of negligible value in the treatment of acute                                    overdosage with lidocaine HCl.</paragraph>
                        <paragraph>The oral LD
         
 
  
         
 
  <sub>50</sub> of lidocaine HCl in non-fasted                                    female rats is 459 (346 to 773) mg/kg (as the salt) and 214 (159                                    to 324) mg/kg (as the salt) in fasted female rats.
        

 
        

 </paragraph>
                     </text>
                     <effectiveTime value="20190331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="c73d1650-a10b-4fb4-82ef-e510975e8225">
               <id root="96c5a900-9627-d713-e053-2995a90ae267"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION:</title>
               <text>
                  <paragraph>Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of Xylocaine Injection for various types of anesthetic procedures.  The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions.  When larger volumes are required, only solutions containing epinephrine should be used except in those cases where vasopressor drugs may be contraindicated.</paragraph>
                  <paragraph>There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures.  Xylocaine is not approved for this use (see 
       
 
  
       
 
  <content styleCode="bold">
                        <linkHtml href="#aa184fbe-007a-49af-92f0-7028d0fa839c">WARNINGS</linkHtml>
                     </content> and 
       
 
  
       
 
  <content styleCode="bold">
                        <linkHtml href="#c73d1650-a10b-4fb4-82ef-e510975e8225">DOSAGE AND ADMINISTRATION</linkHtml>
                     </content>).
      

 
      

 </paragraph>
                  <paragraph>These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures.  The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required, and the physical condition of the patient.  In all cases the lowest concentration and smallest dose that will produce the desired result should be given.  Dosages should be reduced for children and for the elderly and debilitated patients and patients with cardiac and/or liver disease.</paragraph>
                  <paragraph>The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e., total dose) of local anesthetic used.  Thus, an increase in volume and concentration of Xylocaine Injection will decrease the onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia.  However, increasing the volume and concentration of Xylocaine Injection may result in a more profound fall in blood pressure when used in epidural anesthesia.  Although the incidence of side effects with lidocaine HCl is quite low, caution should be exercised when employing large volumes and concentrations, since the incidence of side effects is directly proportional to the total dose of local anesthetic agent injected.</paragraph>
                  <paragraph>For intravenous regional anesthesia, only the 50 mL single dose vial containing Xylocaine (lidocaine HCl) 0.5% Injection should be used.</paragraph>
               </text>
               <effectiveTime value="20190331"/>
               <component>
                  <section ID="b1f818f0-3a80-4226-b807-5a7fc6c95b58">
                     <id root="96c5a900-9628-d713-e053-2995a90ae267"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>Epidural Anesthesia</title>
                     <text>
                        <paragraph>For epidural anesthesia, only the following dosage forms of Xylocaine Injection are recommended:</paragraph>
                        <paragraph>1% without epinephrine                         10 mL Plastic Ampule
         
 
  
         
 
  <br/>1% without epinephrine                         30 mL single dose solutions
         
 
  
         
 
  <br/>1% with epinephrine 1:200,000             30 mL single dose solutions
         
 
  
         
 
  <br/>1.5% without epinephrine     �                10 mL Plastic Ampule  
         
 
  
         
 
  <br/>1.5% without epinephrine                      20 mL Plastic Ampule
         
 
  
         
 
  <br/>1.5% with epinephrine 1:200,000          30 mL ampules, 30 mL single dose solutions
         
 
  
         
 
  <br/>2% without epinephrine                         10 mL Plastic Ampule
         
 
  
         
 
  <br/>2% with epinephrine 1:200,000             20 mL ampules, 20 mL single dose solutions
        

 
        

 </paragraph>
                        <br/>
                        <paragraph>Although these solutions are intended specifically for epidural anesthesia, they may also be used for infiltration and peripheral nerve block, provided they are employed as single dose units.  These solutions contain no bacteriostatic agent. </paragraph>
                        <paragraph>In epidural anesthesia, the dosage varies with the number of dermatomes to be anesthetized (generally 2 to 3 mL of the indicated concentration per dermatome).</paragraph>
                     </text>
                     <effectiveTime value="20151208"/>
                  </section>
               </component>
               <component>
                  <section ID="c8c33bff-f80c-4625-9b07-b165cf174f8e">
                     <id root="96c5a900-9629-d713-e053-2995a90ae267"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>Caudal and Lumbar Epidural Block</title>
                     <text>
                        <paragraph>As a precaution against the adverse experience sometimes                                    observed following unintentional penetration of the subarachnoid                                    space, a test dose such as 2 to 3 mL of 1.5% lidocaine                                    HCl should be administered at least 5 minutes prior to injecting                                    the total volume required for a lumbar or caudal epidural                                    block.  The test dose should be repeated if the patient                                    is moved in a manner that may have displaced the                                    catheter.  Epinephrine, if contained in the test dose                                    (10 to 15 mcg have been suggested), may serve as a warning of                                    unintentional intravascular injection.  If injected                                    into a blood vessel, this amount of epinephrine is likely to                                    produce a transient “epinephrine response”                                    within 45 seconds, consisting of an increase in heart rate and                                    systolic blood pressure, circumoral pallor, palpitations and                                    nervousness in the unsedated patient.  The sedated                                    patient may exhibit only a pulse rate increase of 20 or more                                    beats per minute for 15 or more seconds.  Patients on                                    beta blockers may not manifest changes in heart rate, but blood                                    pressure monitoring can detect an evanescent rise in systolic                                    blood pressure.  Adequate time should be allowed for                                    onset of anesthesia after administration of each test                                    dose.  The rapid injection of a large volume of                                    Xylocaine Injection through the catheter should be avoided, and,                                    when feasible, fractional doses should be                                    administered.</paragraph>
                        <paragraph>In the event of the known injection of a large volume of                                    local anesthetic solution into the subarachnoid space, after                                    suitable resuscitation and if the catheter is in place, consider                                    attempting the recovery of drug by draining a moderate amount of                                    cerebrospinal fluid (such as 10 mL) through the epidural                                    catheter.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="e75d7fd9-31f2-43ee-85dd-5085795ce1ac">
               <id root="96c5a900-962a-d713-e053-2995a90ae267"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>MAXIMUM RECOMMENDED DOSAGES:</title>
               <effectiveTime value="20151113"/>
               <component>
                  <section ID="bd488a3b-f1a0-4d06-a6e9-71f141780eab">
                     <id root="96c5a900-962b-d713-e053-2995a90ae267"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Adults</title>
                     <text>
                        <paragraph>For normal healthy adults, the individual maximum recommended dose of lidocaine HCl with epinephrine should not exceed 7 mg/kg (3.5 mg/lb) of body weight, and in general it is recommended that the maximum total dose not exceed 500 mg.  When used without epinephrine the maximum individual dose should not exceed 4.5 mg/kg (2 mg/lb) of body weight, and in general it is recommended that the maximum total dose does not exceed 300 mg.  For continuous epidural or caudal anesthesia, the maximum recommended dosage should not be administered at intervals of less than 90 minutes.  When continuous lumbar or caudal epidural anesthesia is used for non-obstetrical procedures, more drug may be administered if required to produce adequate anesthesia.</paragraph>
                        <paragraph>The maximum recommended dose per 90 minute period of lidocaine hydrochloride for paracervical block in obstetrical patients and non-obstetrical patients is 200 mg total.  One half of the total dose is usually administered to each side. Inject slowly, five minutes between sides (see also discussion of paracervical block in 
         
 
  
         
 
  <content styleCode="bold">
                              <linkHtml href="#dee2ae0a-5f79-432b-b723-5b3c3e3ed2ec">PRECAUTIONS</linkHtml>
                           </content>).
        

 
        

 </paragraph>
                        <paragraph>For intravenous regional anesthesia, the dose administered should not exceed 4 mg/kg in adults.</paragraph>
                     </text>
                     <effectiveTime value="20151113"/>
                  </section>
               </component>
               <component>
                  <section ID="c6996fa2-d1df-432d-a635-9bf969f55776">
                     <id root="96c5a900-962c-d713-e053-2995a90ae267"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Children</title>
                     <text>
                        <paragraph>It is difficult to recommend a maximum dose of any drug for children, since this varies as a function of age and weight.  For children over 3 years of age who have a normal lean body mass and normal body development, the maximum dose is determined by the child’s age and weight.  For example, in a child of 5 years weighing 50 lbs the dose of lidocaine HCl should not exceed 75 to 100 mg (1.5 to 2 mg/lb).  The use of even more dilute solutions (i.e., 0.25 to 0.5%) and total dosages not to exceed 3 mg/kg (1.4 mg/lb) are recommended for induction of intravenous regional anesthesia in children.</paragraph>
                        <br/>
                        <paragraph>In order to guard against systemic toxicity, the lowest effective concentration and lowest effective dose should be used at all times.  In some cases it will be necessary to dilute available concentrations with 0.9% sodium chloride injection in order to obtain the required final concentration.</paragraph>
                        <br/>
                        <paragraph>NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit.  The Injection is not to be used if its color is pinkish or darker than slightly yellow or if it contains a precipitate.</paragraph>
                        <table ID="t1" width="100%">
                           <caption>Table 1: Recommended Dosages
</caption>
                           <col width="4.000%" align="left"/>
                           <col width="45.000%" align="left"/>
                           <col width="17.000%" align="left"/>
                           <col width="17.000%" align="left"/>
                           <col width="17.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Toprule Lrule Rrule" valign="top"/>
                                 <td colspan="3" align="center" styleCode="Toprule Rrule" valign="top">Xylocaine (lidocaine hydrochloride)
            
    
     
            
    
     <br/>Injection (without epinephrine)

           
   
    
           
   
    </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Botrule Lrule Rrule" valign="top">Procedure
</td>
                                 <td align="center" styleCode="Botrule" valign="top">Conc (%)
</td>
                                 <td align="center" styleCode="Botrule" valign="top">Vol (mL)
</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">Total Dose (mg)
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">Infiltration
</td>
                                 <td align="center" valign="top"/>
                                 <td align="center" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Percutaneous
</td>
                                 <td align="center" valign="top">0.5 or 1
</td>
                                 <td align="center" valign="top">1 to 60
</td>
                                 <td align="center" styleCode="Rrule" valign="top">5 to 300
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Intravenous regional
</td>
                                 <td align="center" valign="top">0.5
</td>
                                 <td align="center" valign="top">10 to 60
</td>
                                 <td align="center" styleCode="Rrule" valign="top">50 to 300
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">Peripheral Nerve Blocks, e.g.,
</td>
                                 <td align="center" valign="top"/>
                                 <td align="center" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Brachial
</td>
                                 <td align="center" valign="top">1.5
</td>
                                 <td align="center" valign="top">15 to 20
</td>
                                 <td align="center" styleCode="Rrule" valign="top">224 to 300
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Dental
</td>
                                 <td align="center" valign="top">2
</td>
                                 <td align="center" valign="top">1 to 5
</td>
                                 <td align="center" styleCode="Rrule" valign="top">20 to 100
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Intercostal
</td>
                                 <td align="center" valign="top">1
</td>
                                 <td align="center" valign="top">3
</td>
                                 <td align="center" styleCode="Rrule" valign="top">30
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Paravertebral
</td>
                                 <td align="center" valign="top">1
</td>
                                 <td align="center" valign="top">3 to 5
</td>
                                 <td align="center" styleCode="Rrule" valign="top">30 to 50
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Pundendal (each side)
</td>
                                 <td align="center" valign="top">1
</td>
                                 <td align="center" valign="top">10
</td>
                                 <td align="center" styleCode="Rrule" valign="top">100
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">Paracervical
</td>
                                 <td align="center" valign="top"/>
                                 <td align="center" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Obstetrical analgesia (each side)
</td>
                                 <td align="center" valign="top">1
</td>
                                 <td align="center" valign="top">10
</td>
                                 <td align="center" styleCode="Rrule" valign="top">100
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">Sympathetic Nerve Blocks, e.g.,
</td>
                                 <td align="center" valign="top"/>
                                 <td align="center" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Cervical (stellate ganglion)
</td>
                                 <td align="center" valign="top">1
</td>
                                 <td align="center" valign="top">5
</td>
                                 <td align="center" styleCode="Rrule" valign="top">50
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Lumbar
</td>
                                 <td align="center" valign="top">1
</td>
                                 <td align="center" valign="top">5 to 10
</td>
                                 <td align="center" styleCode="Rrule" valign="top">50 to 100
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">Central Neural Blocks
</td>
                                 <td align="center" valign="top"/>
                                 <td align="center" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Epidural*
</td>
                                 <td align="center" valign="top"/>
                                 <td align="center" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">   Thoracic
</td>
                                 <td align="center" valign="top">1
</td>
                                 <td align="center" valign="top">20 to 30
</td>
                                 <td align="center" styleCode="Rrule" valign="top">200 to 300
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">   Lumbar
</td>
                                 <td align="center" valign="top"/>
                                 <td align="center" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">       Analgesia
</td>
                                 <td align="center" valign="top">1
</td>
                                 <td align="center" valign="top">25 to 30
</td>
                                 <td align="center" styleCode="Rrule" valign="top">250 to 300
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">       Anesthesia
</td>
                                 <td align="center" valign="top">1.5
</td>
                                 <td align="center" valign="top">15 to 20
</td>
                                 <td align="center" styleCode="Rrule" valign="top">225 to 300
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top"/>
                                 <td align="center" valign="top">2
</td>
                                 <td align="center" valign="top">10 to 15
</td>
                                 <td align="center" styleCode="Rrule" valign="top">200 to 300
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" styleCode="Lrule Rrule" valign="top">Caudal
</td>
                                 <td align="center" valign="top"/>
                                 <td align="center" valign="top"/>
                                 <td align="center" styleCode="Rrule" valign="top"/>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule" valign="top"/>
                                 <td align="left" styleCode="Rrule" valign="top">Obstetrical analgesia
</td>
                                 <td align="center" valign="top">1
</td>
                                 <td align="center" valign="top">20 to 30
</td>
                                 <td align="center" styleCode="Rrule" valign="top">200 to 300
</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule" valign="top"/>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Surgical anestheai
</td>
                                 <td align="center" styleCode="Botrule" valign="top">1.5
</td>
                                 <td align="center" styleCode="Botrule" valign="top">15 to 20
</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">225 to 300
</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>THE ABOVE SUGGESTED CONCENTRATIONS AND VOLUMES SERVE ONLY AS A GUIDE. OTHER VOLUMES AND CONCENTRATIONS MAY BE USED PROVIDED THE TOTAL MAXIMUM RECOMMENDED DOSE IS NOT EXCEEDED.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20190331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ccb02173-78b2-4d50-8918-2090d622cb9b">
               <id root="96c5a900-962d-d713-e053-2995a90ae267"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>STERILIZATION, STORAGE AND TECHNICAL PROCEDURES:</title>
               <text>
                  <paragraph>Disinfecting agents containing heavy metals, which cause release of respective ions (mercury, zinc, copper, etc) should not be used for skin or mucous membrane disinfection as they have been related to incidents of swelling and edema.  When chemical disinfection of multi-dose vials is desired, either isopropyl alcohol (91%) or ethyl alcohol (70%) is recommended.  Many commercially available brands of rubbing alcohol, as well as solutions of ethyl alcohol not of USP grade, contain denaturants which are injurious to rubber and therefore are not to be used. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage forms listed as Xylocaine-MPF indicate single dose solutions that are 
        
  
   
        
  
   <content styleCode="underline">M</content>ethyl 
        
  
   
        
  
   <content styleCode="underline">P</content>araben 
        
  
   
        
  
   <content styleCode="underline">F</content>ree (MPF).
       
 
  
       
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20151113"/>
            </section>
         </component>
         <component>
            <section ID="ba6d1853-e0e0-452c-b77c-4ed4f9cda6ad">
               <id root="ec4e527a-ea2b-410c-92a7-0d342f2b1692"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED:</title>
               <text>
                  <paragraph>Xylocaine® (lidocaine HCl Injection, USP)
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="20.555%" align="left"/>
                     <col width="21.505%" align="left"/>
                     <col width="26.182%" align="left"/>
                     <col width="31.758%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Product Code</content>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Unit of Sale</content>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Each</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">PRX480527
</td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-485-26
          
    
     
          
    
     <br/>Unit of 25

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">1%
          
    
     
          
    
     <br/>200 mg per 20 mL 
          
    
     
          
    
     <br/>(10 mg per mL)

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-485-41
          
    
     
          
    
     <br/>20 mL Multiple Dose Vial

         
   
    
         
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">PRX480627
</td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-486-26
          
    
     
          
    
     <br/>Unit of 25

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">2%
          
    
     
          
    
     <br/>400 mg per 20 mL 
          
    
     
          
    
     <br/>(20 mg per mL)
          
    
     
          
    
     <br/>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-486-41
          
    
     
          
    
     <br/>20 mL Multiple Dose Vial

         
   
    
         
   
    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Xylocaine® -MPF (lidocaine HCl Injection, USP)
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="20.555%" align="left"/>
                     <col width="21.505%" align="left"/>
                     <col width="26.182%" align="left"/>
                     <col width="31.758%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Product Code</content>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Unit of Sale</content>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Each</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">PRX491227
</td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-492-16
          
    
     
          
    
     <br/>Unit of 25

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">1%
          
    
     
          
    
     <br/>20 mg per 2 mL 
          
    
     
          
    
     <br/>(10 mg per mL)

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-492-41<br/>2 mL Single Dose Vial

         
   
    
         
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">PRX491257
</td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-492-36
          
    
     
          
    
     <br/>Unit of 25

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">1%
          
    
     
          
    
     <br/>50 mg per 5 mL
          
    
     
          
    
     <br/> (10 mg per mL)

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-492-43<br/>5 mL Single Dose Vial

         
   
    
         
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">PRX491237
</td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-492-26
          
    
     
          
    
     <br/>Unit of 25

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">1%
          
    
     
          
    
     <br/>300 mg per 30 mL 
          
    
     
          
    
     <br/>(10 mg per mL)

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-492-45
          
    
     
          
    
     <br/>30 mL Single Dose Vial

         
   
    
         
   
    </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">PRX491507
</td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-495-26
          
    
     
          
    
     <br/>Unit of 25

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">2%
          
    
     
          
    
     <br/>100 mg per 5 mL 
          
    
     
          
    
     <br/>(20 mg per mL)

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-495-41
          
    
     
          
    
     <br/>5 mL Single Dose Vial

         
   
    
         
   
    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Xylocaine® (lidocaine HCl and epinephrine Injection, USP) with Epinephrine 1:100,000
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="20.555%" align="left"/>
                     <col width="21.505%" align="left"/>
                     <col width="26.182%" align="left"/>
                     <col width="31.758%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Product Code</content>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Unit of Sale</content>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">
                              <content styleCode="bold">Each</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">PRX480227
</td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-482-26
          
    
     
          
    
     <br/>Unit of 25

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">1% 
          
    
     
          
    
     <br/>200 mg per 20 mL 
          
    
     
          
    
     <br/>(10 mg per mL)

         
   
    
         
   
    </td>
                           <td align="left" styleCode="Toprule Botrule Rrule Lrule" valign="top">NDC 63323-482-41
          
    
     
          
    
     <br/>20 mL Multiple Dose Vial

         
   
    
         
   
    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>All solutions should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. </paragraph>
                  <paragraph>Protect from light.</paragraph>
                  <paragraph>The brand names mentioned in this document are the trademarks of their respective owners.
       
 
  
       
 
  <br/>PremierProRx
       
 
  
       
 
  <sup>®</sup> is a registered trademark of Premier Healthcare Alliance, L.P., used under license.
      

 
      

 </paragraph>
               </text>
               <effectiveTime value="20220915"/>
            </section>
         </component>
         <component>
            <section ID="b1924065-007d-4617-ba67-1bd2ad70d715">
               <id root="44b6d284-b4df-413b-bc81-eea41e823b88"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM3"/>
                  </paragraph>
                  <paragraph>Lake Zurich, IL 60047
  
       
 
  <br/>
                     <br/>
                     <br/>
                     <br/>
                     <linkHtml href="http://www.fresenius-kabi.com/us">www.fresenius-kabi.com/us</linkHtml>
                  </paragraph>
                  <paragraph>451477A
  
       
 
  <br/>
                     <br/>
Revised: March 2019
  
       
 
  <br/>
                     <br/>
                     <br/>
                     <br/>
                     <renderMultiMedia referencedObject="MM4"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Fresenius Kabi Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>PremierPro Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="b5e7f4ea-9cb9-44c9-9f35-948b85d88e5d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine with Epinephrine 20 mL Multiple Dose Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">482</content>-41
  
       
 
  <br/>
                     <br/>
PRX480227
 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>® </sup>
                     </content>
                     <content styleCode="bold">(lidocaine HCl and epinephrine Injection, USP)
   
        
  
   <br/>
                        <br/>
with Epinephrine 1:100,000 
  
       
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1% 200 mg per 20 mL (10 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block
   
        
  
   <br/>
                        <br/>
Not for Caudal or Epidural Use
  
       
 
  </content>
                     <br/>
                     <br/>
                     <content styleCode="bold">20 mL</content> Multiple Dose Vial Rx only
 
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm05"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm05">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine with Epinephrine 20 mL Multiple Dose Vial Label
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="d7027ee6-7242-48a7-a8d6-3b479aa46a55"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine with Epinephrine 20 mL Multiple Dose Vial Tray Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">482</content>-26
  
       
 
  <br/>
                     <br/>
PRX480227
 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>® </sup>
                     </content>
                     <content styleCode="bold">(lidocaine HCl and epinephrine Injection, USP)
   
        
  
   <br/>
                        <br/>
with Epinephrine 1:100,000 
  
       
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1% 200 mg per 20 mL (10 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block Not for Caudal or Epidural Use</content>
                     <br/>
                     <br/>
Rx only
 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">25</content> Multiple Dose Vials, 
  
       
 
  <content styleCode="bold">20 mL</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm06"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm06">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine with Epinephrine 20 mL Multiple Dose Vial Tray Label
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="b2e94591-812e-41eb-ab13-017927d2847a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 20 mL Multiple Dose Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">485</content>-41
 
      

 </paragraph>
                  <paragraph>PRX480527</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine 
   
        
  
   <sup>®</sup> (lidocaine HCl Injection, USP) 
  
       
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1% 200 mg per 20 mL (10 mg per mL) </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Not for Caudal or Epidural Use</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">20 mL</content> Multiple Dose Vial
 
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm07"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm07">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 20 mL Multiple Dose Vial Label
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="f74ffd85-f5a4-4770-90a0-b124cac5e01c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 20 mL Multiple Dose Vial Tray Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">485</content>-26
 
      

 </paragraph>
                  <paragraph>PRX480527</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <sup>® </sup>
                     <content styleCode="bold">(lidocaine HCl Injection, USP)
   
        
  
   <br/>
                        <br/>
1% 200 mg per 20 mL (10 mg per mL) 
  
       
 
  </content>
                     <br/>
                     <br/>
                     <content styleCode="bold">For Infiltration and Nerve Block</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Not for Caudal or Epidural Use</content>
                     <br/>
                     <br/>
Rx only
 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">25</content> Multiple Dose Vials, 
  
       
 
  <content styleCode="bold">20 mL</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm08"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm08">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 20 mL Multiple Dose Vial Tray Label
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s12">
               <id root="cef10430-315e-42de-852d-c61fa80a8e37"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 20 mL Multiple Dose Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">486</content>-41
 
      

 </paragraph>
                  <paragraph>PRX480627</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine 
   
        
  
   <sup>®</sup> (lidocaine HCl Injection, USP) 
  
       
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2% 400 mg per 20 mL (20 mg per mL) </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Not for Caudal or Epidural Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">20 mL</content> Multiple Dose Vial Rx only
 
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm09"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm09">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 20 mL Multiple Dose Vial Label
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="31411a2f-c2b4-4fe4-9968-093a5ec2e5a0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 20 mL Multiple Dose Vial Tray Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">486</content>-26
 
      

 </paragraph>
                  <paragraph>PRX480627</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine 
   
        
  
   <sup>®</sup> (lidocaine HCl Injection, USP) 
  
       
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2% 400 mg per 20 mL (20 mg per mL) </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Not for Caudal or Epidural Use</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">25</content> Multiple Dose Vials, 
  
       
 
  <content styleCode="bold">20 mL</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm10"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm10">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 20 mL Multiple Dose Vial Tray Label
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="be4ea8bc-6051-40f8-88a7-c21e91f3a824"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine – MPF 2 mL Single Dose Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 63323-<content styleCode="bold">492</content>-41
</paragraph>
                  <paragraph>PRX491227
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">- MPF (lidocaine HCl Injection, USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1% 20 mg per 2 mL (10 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block Including Caudal and Epidural Use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mL</content> Single Dose Vial
</paragraph>
                  <renderMultiMedia ID="f11" referencedObject="mm11"/>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm11">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine – MPF 2 mL Single Dose Vial Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="xyl02-0003-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="6ee1375c-356e-4e3d-b31d-bcbaa2c4d0bf"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine – MPF 2 mL Single Dose Vial Tray Label</content>
                  </paragraph>
                  <paragraph>NDC 63323-<content styleCode="bold">492</content>-16
</paragraph>
                  <paragraph>PRX491227
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">- MPF (lidocaine HCl Injection, USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1% 20 mg per 2 mL (10 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block Including Caudal and Epidural Use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Methylparaben Free</content>
                  </paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>
                     <content styleCode="bold">25 Single Dose Vials, 2 mL</content>
                  </paragraph>
                  <renderMultiMedia ID="f12" referencedObject="mm12"/>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm12">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine – MPF 2 mL Single Dose Vial Tray Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="xyl02-0003-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="307058a5-f2ac-4853-bfdc-3627a1468e51"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine – MPF 5 mL Single Dose Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 63323-<content styleCode="bold">492</content>-43
</paragraph>
                  <paragraph>PRX491257
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">- MPF (lidocaine HCl Injection, USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1% 50 mg per 5 mL (10 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block Including Caudal and Epidural Use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Methylparaben Free</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL</content> Single Dose Vial
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <renderMultiMedia ID="f13" referencedObject="mm13"/>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm13">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine – MPF 5 mL Single Dose Vial Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="xyl02-0003-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="5fa08c51-4b46-4caf-b5c2-f6c1debe99d8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine – MPF 5 mL Single Dose Vial Tray Label</content>
                  </paragraph>
                  <paragraph>NDC 63323-<content styleCode="bold">492</content>-36
</paragraph>
                  <paragraph>PRX491257
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">- MPF (lidocaine HCl Injection, USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1% 50 mg per 5 mL (10 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block Including Caudal and Epidural Use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Methylparaben Free</content>
                  </paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>
                     <content styleCode="bold">25 Single Dose Vials, 5 mL</content>
                  </paragraph>
                  <renderMultiMedia ID="f14" referencedObject="mm14"/>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm14">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine – MPF 5 mL Single Dose Vial Tray Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="xyl02-0003-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s18">
               <id root="e7bee694-85f2-40ff-87f5-1809b53337fb"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 5 mL Single Dose Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">495</content>-41
 
      

 </paragraph>
                  <paragraph>PRX491507</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>® </sup>
                     </content>
                     <content styleCode="bold">-MPF (lidocaine HCl Injection, USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2% 100 mg per 5 mL (20 mg per mL)</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">For Infiltration and Nerve Block Including Caudal and Epidural Use.</content>
                  </paragraph>
                  <paragraph>Methylparaben Free</paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL</content> Single Dose Vial Rx only
 
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm15"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm15">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 5 mL Single Dose 
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s19">
               <id root="2a8242e6-92d8-4759-9092-4d850acefb07"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 5 mL Single Dose Vial Tray Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">495</content>-26
 
      

 </paragraph>
                  <paragraph>PRX491507</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">-MPF (lidocaine HCl Injection, USP)
   
        
  
   <br/>
                        <br/>
2% 100 mg per 5 mL (20 mg per mL) 
  
       
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Including Caudal and Epidural Use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Methylparaben Free</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">25 Single Dose Vials, 5 mL</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm16"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm16">
                     <text>495
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s20">
               <id root="47d48e9b-7ef9-4613-836b-38a988f18a8a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 30 mL Single Dose Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">492</content>-45
  
       
 
  <br/>
                     <br/>
PRX491237
 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>® </sup>
                     </content>
                     <content styleCode="bold">-MPF (lidocaine HCl Injection, USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1% 300 mg per 30 mL (10 mg per mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block Including Caudal and Epidural Use.</content>
                     <br/>
                     <br/>
Methylparaben Free
 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 mL</content> Single Dose Vial Rx only
 
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm17"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm17">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 30 mL Single Dose Vial Label
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s21">
               <id root="96ba683e-3b89-4015-aea4-c6b66ec41c73"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 30 mL Single Dose Vial Tray Label</content>
                  </paragraph>
                  <paragraph>NDC 63323- 
  
       
 
  <content styleCode="bold">492</content>-26
 
      

 </paragraph>
                  <paragraph>PRX491237</paragraph>
                  <paragraph>
                     <content styleCode="bold">Xylocaine</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">-MPF (lidocaine HCl Injection, USP)
   
        
  
   <br/>
                        <br/>
1% 300 mg per 30 mL (10 mg per mL) 
  
       
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Infiltration and Nerve Block Including Caudal and Epidural Use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Methylparaben Free</content>
                     <br/>
                     <br/>
Rx only
 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">25</content> Single Dose Vials, 
  
       
 
  <content styleCode="bold">30 mL</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm18"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="mm18">
                     <text>PACKAGE LABEL – PRINCIPAL DISPLAY – Xylocaine 30 mL Single Dose Vial Tray Label
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="xyl02-0003-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>